Design Therapeutics, Inc. (DSGN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Design Therapeutics, Inc. (“Design” or “the Company”) (NASDAQ: DSGN). Investors who purchased Design securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Design has violated federal securities laws.
Investigation Details:
On August 14, 2023, Design issued a press release announcing that the Company will alter the formulation of its Phase 1 Fredreich’s ataxia candidate DT-216 due to injection site reactions, reporting that five cases of injection site thrombophlebitis (blood clot in veins) were observed in the Phase 1 MAD clinical trial. On this news, Design Therapeutics’ stock price fell $5.17 per share, or 70.46%, to close at $2.17 per share on August 15, 2023.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Design securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]